BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 27716172)

  • 1. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
    Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
    BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
    Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
    Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
    J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
    Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
    Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
    Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
    Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
    Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
    Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
    Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
    J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
    Asahina A; Etoh T; Igarashi A; Imafuku S; Saeki H; Shibasaki Y; Tomochika Y; Toyoizumi S; Nagaoka M; Ohtsuki M;
    J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Zhang J; Tsai TF; Lee MG; Zheng M; Wang G; Jin H; Gu J; Li R; Liu Q; Chen J; Tu C; Qi C; Zhu H; Ports WC; Crook T
    J Dermatol Sci; 2017 Oct; 88(1):36-45. PubMed ID: 28558978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
    Abe M; Nishigori C; Torii H; Ihn H; Ito K; Nagaoka M; Isogawa N; Kawaguchi I; Tomochika Y; Kobayashi M; Tallman AM; Papp KA
    J Dermatol; 2017 Nov; 44(11):1228-1237. PubMed ID: 28714180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
    Griffiths CE; Vender R; Sofen H; Kircik L; Tan H; Rottinghaus ST; Bachinsky M; Mallbris L; Mamolo C
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):323-332. PubMed ID: 27600367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
    Valenzuela F; Korman NJ; Bissonnette R; Bakos N; Tsai TF; Harper MK; Ports WC; Tan H; Tallman A; Valdez H; Gardner AC
    Br J Dermatol; 2018 Oct; 179(4):853-862. PubMed ID: 29782642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
    Strober BE; Gottlieb AB; van de Kerkhof PCM; Puig L; Bachelez H; Chouela E; Imafuku S; Thaçi D; Tan H; Valdez H; Gupta P; Kaur M; Frajzyngier V; Wolk R
    Br J Dermatol; 2019 Jan; 180(1):67-75. PubMed ID: 30188571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
    Zhang L; Guo L; Wang L; Jiang X
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
    Menter MA; Papp KA; Cather J; Leonardi C; Pariser DM; Krueger JG; Wohlrab J; Amaya-Guerra M; Kaszuba A; Nadashkevich O; Tsai TF; Gupta P; Tan H; Valdez H; Mallbris L; Tatulych S
    J Drugs Dermatol; 2016 May; 15(5):568-80. PubMed ID: 27168266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
    Feldman SR; Thaçi D; Gooderham M; Augustin M; de la Cruz C; Mallbris L; Buonanno M; Tatulych S; Kaur M; Lan S; Valdez H; Mamolo C
    J Am Acad Dermatol; 2016 Dec; 75(6):1162-1170.e3. PubMed ID: 27692733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.